The abstract is read at the publisher; the summary is JClub's.
In adults with markedly treatment-resistant major depressive disorder (N=493), adjunctive active vagus nerve stimulation over 12 months improved symptoms, function, and quality of life versus sham, with multiple favorable percentages.
- Why it matters: Markedly treatment-resistant depression has high relapse risk and limited options, and RECOVER addresses whether adjunctive VNS provides measurable benefit beyond sham in this difficult population.
- What they did: A 12-month triple-blind randomized trial compared adjunctive active versus sham VNS, using prespecified and additional outcomes across symptom, function, and QoL domains, plus 18- and 24-month durability checks.
- The result: The prespecified primary outcome did not separate groups, but other measures favored active VNS (e.g., 39.6% vs. 30.7% and 45.4% vs. 37.1%), and >80% of responders at 12 months retained benefit at 18 and 24 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.